

# News Release

## News Release

CONTACT: Andrew Bright  
+ 1 (484) 530 3922  
[andrew.bright@oncura.com](mailto:andrew.bright@oncura.com)  
[www.oncura.com](http://www.oncura.com)

### **ONCURA™ introduces innovations in prostate cancer cryotherapy at the annual meeting of the American Urological Association**

Philadelphia (May 19, 2004) — As the global leader in minimally invasive prostate cancer treatment ONCURA has an extensive product development program dedicated to improving quality of life for the many men who require treatment each year. At this month's annual meeting of the American Urological Association (AUA) in San Francisco, ONCURA introduced innovations that will increase the utility of their unique 17 gauge CryoNeedle™ technology.

These innovations included an increase in the size of the therapeutic ice ball generated by their 17 gauge CryoNeedle, various other enhancements that are designed to decrease the time a patient is required to spend in the operating room, as well as a new work station that offers the physician an opportunity to customize each patient's treatment through the use of ultrasound imaging and sophisticated computer programming.

“Our minimally invasive 17 gauge CryoNeedles are increasingly used for the treatment of prostate cancer”, said Jim McGlone, President and CEO of ONCURA. He added, “The introduction of our IceRod™ 17 gauge CryoNeedle allows the generation of longer therapeutic ice balls. This, along with the other innovations introduced at AUA will allow our customers to increase their operational efficiency while maintaining their focus on patient care.”

The technology enhancements introduced at AUA focus on the key areas of ultrasound visualization of the prostate, ice ball size, needle function, post operative care and treatment planning. Alone, each represents a technology improvement; together they signify ONCURA's commitment to long-term product development and improvement. Investment in technologies that improve patient management and outcomes is fundamental to ONCURA's success.

ONCURA, a business of Amersham plc, was created through the merger of Amersham's brachytherapy business with Galil Medical Ltd's urology business. Headquartered in the United States, ONCURA operates as an independent business of Amersham plc, with Galil holding a minority position of 25 percent. ONCURA has a major presence in the treatment of prostate cancer. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.